Transporters as Transceptors
============================

Many nutrients are shuttled across the plasma membrane into the cytosol by transporters. The presence of nutrients can, however, also often be detected on the outside of the cell by classical signal-transducing receptors. The concept of overlap between these groups was highlighted by the discovery in yeast of transporter-related receptors, now known as transceptors, which have now been identified in a range of higher organisms (reviewed in [@B35]). In some cases, transceptor function appears to be linked to transport ability, but in others, only binding, and not transport, may be necessary (see also **Figure [1C](#F1){ref-type="fig"}**). Below we review the evidence that members of the PAT (SLC36) and SNAT (SLC38) amino acid transporter families act as transceptors to control mTORC1 signaling and that this takes place on intracellular membranes.

Specific Solute Carriers Transport Amino Acids and Control mTorc1-Mediated Homeostasis
======================================================================================

[S]{.ul}o[l]{.ul}ute [C]{.ul}arriers ([SLC]{.ul}s) are transmembrane transporters required to maintain intracellular homeostasis through their ability to translocate small soluble molecules such as nutrients, drugs and waste products across lipid bilayers. SLCs are secondary active or facilitative transporters, employing a second substrate or an electrochemical gradient, respectively, to drive transport. They consist of a central pore and gating system that allows the passage of substrates in a regulated manner via conformational changes rather than the opening of a channel (**Figure [1A](#F1){ref-type="fig"}**).

![Transporters, pathetic flies and transceptors. **(A)** Schematic model of transporter switching between outward and inward facing conformations (upper and lower in gray), enabling molecules such as amino acids (AA) to be taken across lipid bilayers. The binding of such substrates is thought to stabilize an intermediate conformation (middle in red). Such transporters can function as symporters, co-transporting protons for some PATs and sodium ions for at least some SNATs. These ions determine the directionality of transport. **(B)** PAT amino acid transporter gene, *pathetic*, is required for normal growth *in vivo*. In comparison to normal controls (cont; middle fly) flies homozygous for the hypomorphic mutation, *pathetic^KG06640^* (KG/KG; lower fly) are small, or when heterozygous with a chromosomal deficiency (Df) removing the *pathetic* gene (KG/Df; upper fly) are even smaller. This small fly phenotype can be rescued by expression of a *pathetic* transgene. Mutations in other mTORC1 signaling pathway components also lead to small fly or small pupal phenotypes, for example, *S6 kinase* ([@B23]) and *mTOR* ([@B42]). This panel is reproduced with permission from the journal Development ([@B11]). **(C)** Schematic model showing how PATs and SNATs may act as transceptors to activate mTORC1. Note that the molecular mechanism by which PATs and SNATs act as transceptors is currently unknown. The binding and/or translocation of amino acids or other substrates by PAT and SNAT transporters presumably induces specific conformational changes that generate a signal. Here, for illustration, we assume this signal is transmitted in the intermediate conformation (red; **A**), which may be formed during the transport cycle. The transceptor conformation facilitates the recruitment of membrane-bound sensing complex components (already assembled in a complex; [@B44]), cytoplasmic sensing complex components and mTORC1 constituents. This leads to the formation of a functional sensing complex that can respond to amino acid signals from the lumen of the intracellular compartment (where extracellular amino acids can rapidly accumulate; [@B44]) to activate mTORC1 signaling and drive cell growth.](fphar-09-00640-g001){#F1}

The SLC superfamily has been divided into over fifty SLC families ([@B25]), based on sequence homology. Members of individual families often have properties in common. One of these is their mechanism of transport, for example, whether they transport their substrate in symport with specific ions. Another is that their substrates, for example, nutrients, metabolites or drugs, have similar chemical features. It has been estimated that over 25% of SLCs transport amino acids as their primary substrates ([@B10]). Some have broad amino acid specificity (see [@B8]), including CD98 heterodimeric transporters and SLC6A14 ([@B33]). Others are highly selective, for example, the [P]{.ul}roton-assisted [A]{.ul}mino acid [T]{.ul}ransporter family ([PAT]{.ul} or SLC36), with prototypical substrates, alanine, glycine and proline, and the [S]{.ul}odium-coupled [N]{.ul}eutral [A]{.ul}mino acid [T]{.ul}ransporter ([SNAT]{.ul} or SLC38) family, which co-transports small neutral amino acids, such as alanine, glutamine, serine, glycine, methionine, and threonine together with sodium ions. In addition to acting as building blocks for protein synthesis, intracellular amino acids are potent activators of a major signaling cascade, which controls this very same process, involving [m]{.ul}echanistic [T]{.ul}arget [o]{.ul}f [R]{.ul}apamycin [C]{.ul}omplex [1]{.ul} ([mTORC1]{.ul}). mTORC1 is also activated by growth factor signaling and promotes mRNA translation by increasing the number and activity of ribosomes to stimulate cell growth and proliferation ([@B13]). While early studies implicated leucine as a major mTORC1 activator ([@B15]; [@B7]; [@B2]), other amino acids are now known to be involved, including arginine ([@B38]; [@B5]), glutamine and serine ([@B19]; [@B28]; [@B9]).

Pat Amino Acid Transporters Control Growth and mTorc1 Signaling
===============================================================

In 2005, an *in vivo* genetic screen was undertaken in the fruit fly, *Drosophila melanogaster*, by overexpressing amino acid transporters from a broad range of SLC families, to identify positive regulators of mTORC1 activity and growth ([@B11]). Members of the PAT (SLC36) family were highlighted as particularly potent growth-promoting transporters.

This was curious, because the rationale of the screen had been to identify cell surface transporters that deliver amino acids to intracellular mTORC1, but the known properties of the two characterized mammalian PATs, PAT1 (SLC36A1), and PAT2 (SLC36A2) were at odds with this idea. On account of its subcellular localisation in rat brain tissue, the first mammalian PAT identified was named [ly]{.ul}sosomal [a]{.ul}mino [a]{.ul}cid [t]{.ul}ransporter 1 ([Lyaat-1]{.ul}; [@B30]), now renamed PAT1. Furthermore, PAT1 and PAT2 transport amino acids in symport with protons, a mechanism that favors transport from the acidic lumens of late endosomes and lysosomes (LELs) into the cytosol. In fast-growing cultured human cells, PAT1 co-localizes with LAMP1, a marker of LELs ([@B24]). GFP-tagged fly PATs are also predominantly located intracellularly. These characteristics raised the question of whether PATs might act to promote growth from inside cells (reviewed in [@B12]).

Two fly PATs, CG1139 and CG3424, were highlighted in the genetic screen; they share sequence similarity with all members of the human PAT family ([@B11]). Adult flies carrying a mutation in the ubiquitously expressed *CG3424* were growth-retarded (**Figure [1B](#F1){ref-type="fig"}**). As is the convention in the *Drosophila* field, *CG3424* was renamed *pathetic* (*path*) to reflect this mutant phenotype; this also reflected the transporter's properties ([PAT]{.ul} with [h]{.ul}igh affinity; see below). Amino acid levels in fly food are likely to modulate the effects of sensors on mTORC1-associated growth. Indeed, the Parrish group has reported that flies homozygous for the same *path* mutant grow to normal size under their culture conditions. They did, however, show that *path* is required for the growth of large, but not small, dendrites in flies, highlighting a selective requirement for Pathetic under these conditions, when exceptional levels of growth are needed ([@B22]).

Genetic experiments in which both *path* and *CG1139* overexpression are combined with changes in mTORC1 signaling components suggest these transporters activate mTORC1 ([@B11]). Human PAT1 and PAT4 (SLC36A4), which are both ubiquitously expressed, also promote cell proliferation and mTORC1 signaling, based on genetic knock down and overexpression in cultured human cells ([@B18]; [@B9]). Both can also induce growth and modulate mTORC1-dependent functions when overexpressed in flies ([@B18]).

It is worth noting that in contrast to these findings, overexpression of PAT1 has been shown by the Sabatini group to reduce mTORC1 signaling ([@B44]). Although they suggested that amino acid depletion from the lysosome might be responsible, the restricted substrate specificity of PAT1 for alanine, glycine and proline transport does not support this view. An alternative explanation is that high levels of PAT1 produce a type of 'dominant negative effect', by interfering with the assembly of complete PAT-mTORC1 growth-promoting complexes. Such a phenomenon was reported by [@B11], where overexpressing one copy of a PAT causes increased growth in the wing *in vivo*, while two copies reduce growth (see Supplementary Figure [1](#SM1){ref-type="supplementary-material"} and further discussion in [@B13]). Overexpression of abnormally high levels of the *Drosophila* homolog of mTOR has also been shown to inhibit growth. This was proposed to be due to the high levels of mTOR binding and titrating away factors essential for normal mTOR function, so that assembly of complete functional complexes was reduced ([@B17]). These experiments emphasize the importance of controlling PAT transporter levels when assessing effects on mTORC1 and growth, suggesting that simple transport may not underpin the growth regulatory properties of these molecules.

Pat and Snat Transceptors Can Regulate mTorc1 Signaling
=======================================================

The transport characteristics of fly PAT CG1139 are very similar to those of characterized mammalian PATs when expressed in the heterologous *Xenopus* oocyte system ([@B11]). PATH, however, behaves very differently. It has a much higher affinity for alanine than CG1139, coupled with much lower transport capacity. Indeed PATH was predicted to increase bulk intracellular amino acid concentration by less than 0.2% in oocyte experiments. Despite this, PATH activated S6-kinase, an established mTORC1 target, in this system. These findings suggested that PATH might be acting as a transport-independent transceptor (**Figure [1C](#F1){ref-type="fig"}**; [@B11]).

PATH's poor ability to transport amino acids raised the possibility that additional amino acid transporters might control mTORC1 via a transceptor mechanism. Attention focused on human PAT4, which at the time had no known transport substrates. PAT4 was found to exhibit very high substrate affinity and low capacity for proline and the atypical PAT substrate tryptophan, when expressed in *Xenopus* oocytes ([@B26]). PAT4 was also found to transport in an electroneutral manner. These properties were in keeping with the transport characteristics of PATH and led to the suggestion that PAT4, which activates mTORC1 in human cells ([@B18]), may be a functional equivalent of PATH ([@B26]). Alternatively transceptor function may be shared by all members of the PAT family, irrespective of their transport capacity.

Other researchers interested in uncovering the link between amino acid transporters and mTORC1 focused on a member of the SNAT family of transporters called SNAT2 (SLC38A2), and approached the identification of transceptor function from a different angle. There are eleven members of the human SNAT family, although the transport properties of only some of them have been studied in detail ([@B32]). Elegant experiments involving the transport of the non-metabolisable SNAT2 substrate [MeAIB]{.ul} (α-[me]{.ul}thyl[a]{.ul}mino[i]{.ul}so[b]{.ul}utyrate) demonstrated that this compound could activate mTORC1 signaling via SNAT2 during amino acid starvation. Under these specific conditions, MeAIB increased cell proliferation in MCF7 breast cancer and L6 myotubes ([@B27]). Substrate binding and transport alone, therefore, is sufficient for SNAT2 to activate mTORC1, even if the substrate cannot subsequently be utilized in the downstream metabolic pathways that normally act on transported amino acids.

PAT and SNAT families are closely related in their eleven putative transmembrane domains ([@B32]). This may explain why members of both families have transceptor function. Currently the mechanism by which amino acid interaction with PATs and SNATs leads to transceptor activation remains unclear. Presumably, amino acid binding and/or translocation could lead to conformational changes in the transporter and/or altered interaction with an associated protein complex, which then increases mTORC1 signaling (**Figure [1C](#F1){ref-type="fig"}**).

An Amino Acid Sensing Complex on Late Endosomes and Lysosomes Controls mTorc1 Activity
======================================================================================

Reports identifying the human PATs as mTORC1 regulators emerged shortly after their established sites of action, the LELs, were shown to be key places where mTORC1 signaling is controlled by amino acids via the Rag GTPases, central components of an amino acid sensing complex required for mTORC1 recruitment and activation on these compartments ([@B31]). Over the last 10 years the number of components identified in this sensing complex has increased, including membrane-associated components, such as the v-ATPase proton pump. In addition, a range of cytosolic amino acid and glucose sensors has been proposed, including Leucyl-tRNA synthetase ([@B14]), Castors, Sestrins, TSC/Rheb (reviewed in [@B40]) and aldolase ([@B21]).

The presence of an amino acid sensing complex spanning the surface of intracellular compartments raised the possibility that it also sensed nutrients from the luminal face. The LEL lumen is topologically equivalent to the extracellular milieu and so could provide a read-out of the extracellular environment. Indeed, [@B44] have shown that labeled extracellular amino acids enter the LEL lumen within 10 min. Amino acid transporters that span the lipid bilayer and can bind amino acids seemed ideal candidate sensors.

Late Endosomal and Lysosomal Pats and Snats Regulate mTorc1 Signaling
=====================================================================

Human PAT1 was the first amino acid transporter located on LELs, which was shown to interact physically with the Rag GTPases and to be required for amino acid-dependent mTORC1 recruitment to these compartments. It was proposed that it was part of a sensing assembly that detects amino acids in the luminal space of these compartments to activate mTORC1 ([@B18]; [@B24]; **Figure [2](#F2){ref-type="fig"}**).

![Subcellular localisation of PAT and SNAT transporters: amino acid sensors in disguise. Schematic model showing PAT and SNAT amino acid transceptors, which can respond to specific amino acids in the lumen of intracellular compartments by activating mTORC1 and growth via a transport-independent mechanism. Note that the molecular mechanism by which PATs and SNATs act as transceptors is currently unknown. PAT and SNAT transporters have been identified in several different locations in cells, namely the plasma membrane, acidic late endosomes and lysosomes (LELs), and also the Golgi apparatus. In the transceptor model, the binding and/or translocation of specific amino acids or other substrates induces a conformational change that alters interactions with associated proteins and increases mTORC1 signaling. The amino acid sensing complexes associated with SNAT2 have not yet been characterized. Different transporters have been shown to shuttle between compartments; for example, in human cells, PAT1 (plasma membrane and LELs) and SNAT2 (Golgi and plasma membrane), thus modulating their mTORC1-regulatory activity.](fphar-09-00640-g002){#F2}

More recently, a SNAT, SLC38A9, has also been shown to localize to LELs and to strongly interact with the Rag GTPases and other components of the amino acid-sensing mTORC1 super-complex via its cytosolic N-terminal region. This N-terminal interaction with the Ragulator and Rags is, however, insensitive to amino acids ([@B20]; [@B28]; [@B38]). Full-length SLC38A9 transports arginine with low affinity and also glutamine, but its arginine-dependent interactions with the Rags require much lower, more physiological levels of arginine ([@B41]), supporting a transceptor function. A form of SLC38A9 that lacks the N-terminal region (SLC38A9.2) can still physically interact with the v-ATPase and is sensitive to amino acids, suggesting that the transmembrane regions in this molecule, which are the domains conserved between PATs and SNATs, are likely to be central to its amino acid sensing ability ([@B38]). Given the transceptor function attributed to other SNATs and some PATs, it seems likely that SLC38A9 shares a related mTORC1-regulatory transceptor mechanism.

Although the weight of evidence from different systems strongly supports the role of amino acid transporters in transceptor-mediated mTORC1 activation, the limitations of each experimental approach employed also needs to be considered. Transport assays are performed in a heterologous system, such as *Xenopus* oocytes or proteoliposomes, not *in situ*. Experiments in human cell culture are typically performed following complete amino acid starvation and may involve the addition of single amino acids; how this relates to physiological conditions remains unclear. This will be particularly relevant when substrates that bind at different affinities are mixed. Indeed, recent transport studies with SLC38A9 suggest a complex interplay between arginine and other amino acids, such as leucine, which it has now been shown to transport at high affinity ([@B41]). *In vivo* approaches effectively circumvent this problem, but specific mutant transporters or substrates that could distinguish transceptor- and transporter-dependent mechanisms have yet to be developed.

Golgi-Localized Pat4 Can Regulate mTorc1 Signaling
==================================================

The Golgi apparatus provides a second site from which mTORC1 can be activated ([@B36]; [@B19]). Indeed, an analysis of PAT4 revealed that it is strongly localized to the *trans*-Golgi in cancer cell lines ([@B9]). Proximity ligation assays ([@B39]) suggested that PAT4 interacts with Rab1A and mTOR at this location. PAT4 has two properties that distinguish it from the LEL-localized, mTORC1-regulating transporters. First, it has a transport preference for serine and glutamine, the latter being another key amino acid required for metabolism in many cancers ([@B43]). Second, it seems to regulate a form of mTORC1 that has a stronger effect on one of its targets, the translation initiation inhibitor 4E-binding protein 1 (4E-BP1), than on another, the S6-kinase/ribosomal S6 pathway, unlike LEL-localized mTORC1. Given the observation that PAT4 is a high affinity, low capacity transporter, these findings suggest that it represents an alternative mTORC1-regulating transceptor on the Golgi (**Figure [2](#F2){ref-type="fig"}**).

It should also be remembered that other transceptors in the SNAT family that have been assumed to function at the cell surface, have the potential to act as intracellular transceptors. For example, SNAT2 is thought to act at the plasma membrane and to be stored in the Golgi ([@B16]), when not required. It will be important to check that this Golgi-located SNAT2 is not involved in mTORC1 regulation in future studies.

Regulation of Pat and Snat Activity Through Intracellular Shuttling
===================================================================

Another implication of the compartment-specific transceptor functions of PATs and SNATs is that their trafficking within the cell will significantly affect mTORC1-regulatory activity. Although the subcellular localisation of mammalian PATs is reported to vary between cell types ([@B30]; [@B6]; [@B29]), studies investigating the control of that localisation have been limited to overexpression experiments with GFP-tagged PATs in *Drosophila*. Oncogenic signaling through loss of the major tumor suppressor, PTEN, which blocks PI3-kinase signaling, leads to a striking shift in PAT localisation into intracellular compartments. This is accompanied by a synergistic enhancement in growth ([@B24]; reviewed in [@B13]).

It is tempting to speculate that several transporters in the PAT and SNAT families play a dual role: as transporters at the plasma membrane and transceptors inside the cell, with extracellular signals, such as nutrients or growth factors, determining the balance between these two functions. This could be particularly significant in cancer where growing cells must adapt to changes in their microenvironment that are typically not experienced in normal physiological conditions.

Pats and Snats as Therapeutic Targets to Block Cancer Progression
=================================================================

The expression of a growing number of SLC transporters has been implicated in cancer progression, and there has been interest in targeting them to block cancer progression, for example, through effects on 'glutamine addiction' (reviewed in [@B3]) and in metastatic prostate cancer ([@B37]). PAT and SNAT family members are implicated in cancer progression. For example, SNAT1 and SNAT2 are required to support glutaminolysis in cancer cells ([@B4]). In addition, high PAT4 expression is associated with reduced relapse-free survival after colorectal cancer surgery. A detailed analysis of PAT4 function in the colorectal cancer cell line HCT116 suggested that high expression of PAT4 leads to resistance to depletion of glutamine ([@B9]). Cells become more addicted to glutamine as their metabolism switches toward increased glycolysis, the so-called Warburg effect ([@B34]). Therefore, PAT4 may take on a more prominent function in some cancers as they come under nutrient stress, caused for example by reduced blood supply. The role of SLC38A9 in cancer is complex. It appears to be downregulated in colorectal cancer ([@B1]). In pancreatic cancer, however, it has been reported to become essential when macropinocytosis, stimulated by the oncogenic form of K-Ras, becomes the primary mechanism by which tumor cells acquire nutrients, which are released by protein degradation in the lysosome ([@B41]).

Overall, a picture is emerging in which multiple transceptors, which have enhanced function under certain microenvironmental conditions, are likely to be involved in cancer growth. This coupled with their potential synergistic interactions with oncogenic signaling, may provide new therapeutic opportunities to selectively target cancer cells, particularly in combinatorial treatments. Such developments will require a more detailed analysis of the conditions under which their function becomes essential, as well as a better understanding of the transceptor signaling mechanism.

Uncovering the Pat and Snat Transceptor Mechanism
=================================================

A number of research groups around the world have now highlighted different members of the PAT and SNAT families as amino acid-sensing transceptors that can activate mTORC1. The range of evidence and experimental models used strengthens the idea that PATs and SNATs share a common transceptor function. Several technical challenges, however, remain and mean we are some distance from understanding the mechanistic details.

A comprehensive analysis of the structural features in PATs and SNATs mediating transceptor function is needed. Of note is a threonine residue in the first transmembrane domain of SLC38A9, conserved in human and fly PATs as well as other SNATs. As this is essential for amino acid binding, it would also be required for transceptor function ([@B41]). Mutations in residues such as this will be useful in blocking signaling or possibly altering amino acid specificity; dissecting the transceptor mechanism will, however, require an understanding of the conformational changes that amino acids induce.

A second priority is to screen for small molecules that can block transceptor function, with success dependent on the transceptor mechanism. This is illustrated by MeAIB, which competes with SNAT2′s amino acid substrates, but under amino acid starvation can activate its mTORC1-regulatory transceptor function ([@B27]). Finding an inhibitor of transceptor function will require the identification of a molecule that binds to the transporter, but prevents it from adopting the 'transceptor conformation' (**Figure [1C](#F1){ref-type="fig"}**).

Over more than a decade the study of PATs and SNATs has highlighted a new paradigm for transporter function, where these molecules not only function via the assembly of a signaling complex, but also can do this in specific intracellular compartments. Moving forward, we will see whether other nutrient transporters in humans have taken on similar roles during evolution, and whether they also have important roles in disease.
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